



# Emerging Challenges In Primary Care: *2012*

## Activity Evaluation Summary

**CME Activity:** Emerging Challenges in Primary Care: 2012  
Saturday, September 22, 2012  
Renaissance Ft. Lauderdale  
Plantation, FL

**Course Director:** Gregg Sherman, MD

**Date of Evaluation  
Summary:** October 10, 2012



300 NW 70<sup>th</sup> Avenue, Suite 102 • Plantation, Florida 33317  
(954) 723-0057 Phone • (954) 723-0353 Fax  
email: [info@naceonline.com](mailto:info@naceonline.com)

In September 2012, the National Association for Continuing Education (NACE) sponsored a CME program, ***Emerging Challenges in Primary Care: 2012***, in Fort Lauderdale, FL.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about Diabetes, Atrial Fibrillation, Inflammatory Bowel Disease, Osteoporosis, Pulmonary Arterial Hypertension, Alpha-1 Antitrypsin Disorder, ADHD in Adults, and Idiopathic Pulmonary Fibrosis.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Three hundred thirteen healthcare practitioners registered to attend ***Emerging Challenges in Primary Care: 2012*** in Fort Lauderdale, FL. Two hundred one healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. One hundred ninety three completed forms were received. The data collected is displayed in this report.


#### CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 8 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


## What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	134	69.43	69.43
DO	11	5.70	5.70
NP	29	15.03	15.03
PA	12	6.22	6.22
RN	5	2.59	2.59
Other	2	1.04	1.04
Total Valid	193	100.00	100.00




## What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	145	75.13	76.32
Endocrinology	1	0.52	0.53
Rheumatology	0	0.00	0.00
Pulmonology	1	0.52	0.53
Cardiology	7	3.63	3.68
Gastroenterology	2	1.04	1.05
OB/GYN	2	1.04	1.05
Other	32	16.58	16.84
Total Valid	190	98.45	100.00
Total Missing	3	1.55	
Total	193	100.00	




**Upon completion of this activity, I can now - Address the importance of early diagnosis for enhancing outcomes in type 2 diabetes; identify evidence-based strategies for type 2 diabetes management; discuss the role of newer therapies in the pathophysiology and management of type 2 diabetes; and discuss the role of the chronic care model in optimizing diabetes care:**

Label	Frequency	Percent	Valid Percent
Yes	171	88.60	91.44
Somewhat	15	7.77	8.02
Not at all	1	0.52	0.53
Total Valid	187	96.89	100.00
Total Missing	6	3.11	
Total	193	100.00	




**Upon completion of this activity, I can now - Describe existing guidelines and best practices in the diagnosis and treatment of ADHD in adults; identify risks for co-morbidities in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders; plan a pharmacologic treatment program for adults diagnosed with simple ADHD and more complex ADHD that is complicated by co-morbidities; identify psychosocial treatments for adults diagnosed with ADHD:**

Label	Frequency	Percent	Valid Percent
Yes	152	78.76	80.85
Somewhat	35	18.13	18.62
Not at all	1	0.52	0.53
Total Valid	188	97.41	100.00
Total Missing	5	2.59	
Total	193	100.00	




**Upon completion of this activity, I can now - Describe the pathophysiology and impact of AAT deficiency; Define approaches for the early identification of patients with AAT deficiency; Discuss strategies to improve testing in primary care settings; Discuss management of patients with AAT:**

Label	Frequency	Percent	Valid Percent
Yes	159	82.38	83.68
Somewhat	30	15.54	15.79
Not at all	1	0.52	0.53
Total Valid	190	98.45	100.00
Total Missing	3	1.55	
Total	193	100.00	




**Upon completion of this activity, I can now - Address the pathophysiology of PAH; discuss when and how to screen patients for PAH; identify current therapies in the management of PAH; and discuss how to appropriately monitor patients receiving treatment for PAH:**

Label	Frequency	Percent	Valid Percent
Yes	160	82.90	83.33
Somewhat	31	16.06	16.15
Not at all	1	0.52	0.52
Total Valid	192	99.48	100.00
Total Missing	1	0.52	
Total	193	100.00	




**Upon completion of this activity, I can now - Describe the state-of-the-art approach to diagnosing idiopathic pulmonary fibrosis (IPF) from among a range of diffuse parenchymal lung disorders; Define prognostic features for individual IPF patients; Apply appropriate pharmacotherapeutic options for individual IPF patients while having a general understanding of the options under intense investigation; Discuss the role of available non-pharmacological therapies including pulmonary rehabilitation, oxygen supplementation and lung transplantation in IPF management:**

Label	Frequency	Percent	Valid Percent
Yes	153	79.27	82.70
Somewhat	31	16.06	16.76
Not at all	1	0.52	0.54
Total Valid	185	95.85	100.00
Total Missing	8	4.15	
Total	193	100.00	



**Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and non-pharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; use currently available laboratory tests to maximize benefit while minimizing toxicity; employ approaches for effectively communicating the risks and benefits of IBD treatment options and facilitating adherence:**


Label	Frequency	Percent	Valid Percent
Yes	161	83.42	87.98
Somewhat	22	11.40	12.02
Not at all	0	0.00	0.00
Total Valid	183	94.82	100.00
Total Missing	10	5.18	
Total	193	100.00	






**Upon completion of this activity, I can now - Discuss screening strategies for osteoporosis in postmenopausal women; identify candidates for pharmacologic treatment of postmenopausal osteoporosis; evaluate and compare available therapies for osteoporosis; and discuss barriers to adherence and effectiveness of osteoporosis therapy:**

Label	Frequency	Percent	Valid Percent
Yes	161	83.42	92.53
Somewhat	13	6.74	7.47
Not at all	0	0.00	0.00
Total Valid	174	90.16	100.00
Total Missing	19	9.84	
Total	193	100.00	




**Upon completion of this activity, I can now - Use the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); describe the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify appropriate therapeutic interventions for AF patients depending on the level of stroke risk; optimize the long-term management of AF patients receiving antithrombotic therapy:**

Label	Frequency	Percent	Valid Percent
Yes	155	80.31	92.81
Somewhat	9	4.66	5.39
Not at all	3	1.55	1.80
Total Valid	167	86.53	100.00
Total Missing	26	13.47	
Total	193	100.00	




**Overall, I would rate this activity as:**

Label	Frequency	Percent	Valid Percent
Excellent	144	74.61	76.19
Very Good	39	20.21	20.63
Good	6	3.11	3.17
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	189	97.93	100.00
Total Missing	4	2.07	
Total	193	100.00	




**Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?**

Label	Frequency	Percent	Valid Percent
Strongly Agree	120	62.18	63.16
Agree	68	35.23	35.79
Neutral	2	1.04	1.05
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	190	98.45	100.00
Total Missing	3	1.55	
Total	193	100.00	




**Overall, this activity was effective in improving my knowledge in the content areas presented:**

Label	Frequency	Percent	Valid Percent
Strongly Agree	135	69.95	70.68
Agree	56	29.02	29.32
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	191	98.96	100.00
Total Missing	2	1.04	
Total	193	100.00	




## As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	117	60.62	62.57
Agree	66	34.20	35.29
Neutral	4	2.07	2.14
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	187	96.89	100.00
Total Missing	6	3.11	
Total	193	100.00	




## How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	120	62.18	64.17
Somewhat likely	56	29.02	29.95
Unlikely	3	1.55	1.60
Not applicable	8	4.15	4.28
Total Valid	187	96.89	100.00
Total Missing	6	3.11	
Total	193	100.00	




## When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	113	58.55	62.09
1-3 months	46	23.83	25.27
4-6 months	8	4.15	4.40
Not applicable	15	7.77	8.24
Total Valid	182	94.30	100.00
Total Missing	11	5.70	
Total	193	100.00	




## In terms of delivery of the presentation, please rate the effectiveness of the speaker: Frank Lavernia, MD (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	134	69.43	72.43
Very Good	40	20.73	21.62
Good	10	5.18	5.41
Fair	1	0.52	0.54
Unsatisfactory	0	0.00	0.00
Total Valid	185	95.85	100.00
Total Missing	8	4.15	
Total	193	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Oren Mason, MD (ADHD):**

Label	Frequency	Percent	Valid Percent
Excellent	144	74.61	77.01
Very Good	36	18.65	19.25
Good	7	3.63	3.74
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	187	96.89	100.00
Total Missing	6	3.11	
Total	193	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (AAT):**

Label	Frequency	Percent	Valid Percent
Excellent	156	80.83	82.54
Very Good	31	16.06	16.40
Good	2	1.04	1.06
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	189	97.93	100.00
Total Missing	4	2.07	
Total	193	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (PAH):**

Label	Frequency	Percent	Valid Percent
Excellent	154	79.79	81.91
Very Good	33	17.10	17.55
Good	1	0.52	0.53
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	188	97.41	100.00
Total Missing	5	2.59	
Total	193	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Kevin Flaherty, MD (IPF):**

Label	Frequency	Percent	Valid Percent
Excellent	148	76.68	84.57
Very Good	26	13.47	14.86
Good	1	0.52	0.57
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	175	90.67	100.00
Total Missing	18	9.33	
Total	193	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gerald W. Dryden, MD (IBD):**

Label	Frequency	Percent	Valid Percent
Excellent	142	73.58	81.61
Very Good	28	14.51	16.09
Good	3	1.55	1.72
Fair	1	0.52	0.57
Unsatisfactory	0	0.00	0.00
Total Valid	174	90.16	100.00
Total Missing	19	9.84	
Total	193	100.00	



**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Vernon Hershberger, MD (Osteo):**


Label	Frequency	Percent	Valid Percent
Excellent	135	69.95	84.91
Very Good	19	9.84	11.95
Good	5	2.59	3.14
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	159	82.38	100.00
Total Missing	34	17.62	
Total	193	100.00	






**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Jan Basile, MD (A Fib):**

Label	Frequency	Percent	Valid Percent
Excellent	129	66.84	88.97
Very Good	14	7.25	9.66
Good	1	0.52	0.69
Fair	1	0.52	0.69
Unsatisfactory	0	0.00	0.00
Total Valid	145	75.13	100.00
Total Missing	48	24.87	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Frank Lavernia, MD (Diabetes):**

Label	Frequency	Percent	Valid Percent
Excellent	169	87.56	92.86
Very Good	11	5.70	6.04
Good	2	1.04	1.10
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	182	94.30	100.00
Total Missing	11	5.70	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Oren Mason, MD (ADHD):**

Label	Frequency	Percent	Valid Percent
Excellent	162	83.94	88.52
Very Good	18	9.33	9.84
Good	2	1.04	1.09
Fair	0	0.00	0.00
Unsatisfactory	1	0.52	0.55
Total Valid	183	94.82	100.00
Total Missing	10	5.18	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (AAT):**

Label	Frequency	Percent	Valid Percent
Excellent	168	87.05	91.80
Very Good	13	6.74	7.10
Good	2	1.04	1.09
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	183	94.82	100.00
Total Missing	10	5.18	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (PAH):**

Label	Frequency	Percent	Valid Percent
Excellent	168	87.05	89.84
Very Good	17	8.81	9.09
Good	2	1.04	1.07
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	187	96.89	100.00
Total Missing	6	3.11	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Kevin Flaherty, MD (IPF):**

Label	Frequency	Percent	Valid Percent
Excellent	161	83.42	92.00
Very Good	13	6.74	7.43
Good	1	0.52	0.57
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	175	90.67	100.00
Total Missing	18	9.33	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gerald W. Dryden, MD (IBD):**

Label	Frequency	Percent	Valid Percent
Excellent	156	80.83	89.66
Very Good	17	8.81	9.77
Good	0	0.00	0.00
Fair	1	0.52	0.57
Unsatisfactory	0	0.00	0.00
Total Valid	174	90.16	100.00
Total Missing	19	9.84	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Vernon Hershberger, MD (Osteo):**

Label	Frequency	Percent	Valid Percent
Excellent	150	77.72	90.36
Very Good	13	6.74	7.83
Good	2	1.04	1.20
Fair	1	0.52	0.60
Unsatisfactory	0	0.00	0.00
Total Valid	166	86.01	100.00
Total Missing	27	13.99	
Total	193	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jan Basile, MD (A Fib):**

Label	Frequency	Percent	Valid Percent
Excellent	147	76.17	91.88
Very Good	11	5.70	6.88
Good	2	1.04	1.25
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	160	82.90	100.00
Total Missing	33	17.10	
Total	193	100.00	




**Which statement(s) best reflects your reasons for participating in this activity:**

Label	Frequency	Percent	Valid Percent
Topics covered	152	78.76	78.76
Location/ease of access	136	70.47	70.47
Faculty	79	40.93	40.93
Earn CME credits	159	82.38	82.38
Total Valid	193	100.00	100.00



## Future CME activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	108	55.96	59.02
Agree	62	32.12	33.88
Neutral	11	5.70	6.01
Disagree	2	1.04	1.09
Strongly Disagree	0	0.00	0.00
Total Valid	183	94.82	100.00
Total Missing	10	5.18	
Total	193	100.00	



## What is your professional degree?

Comment
BS
CPCI

## What is your specialty?

Comment
Psychiatry
Critical Care
Clinical Care
Internal Medicine
Infectious Disease
Family Medicine
Pediatrics
Addiction
Pathology
Nephrology
Pathology
Emergency Medicine
Neurology
Neuro-Rehab
Pathologist
Trauma
Neurology
Psychiatry
Dermatology
Geriatrics
Hospitalist
Psychiatry
Geriatrics
Occupational Health
Addiction
Internal Medicine
Trauma
Dialysis
Pathology
Urgent Care
Clinical Pathology
Palliative Care

**As a result of this activity, I have learned new strategies for patient care. List these strategies:**

Comment
Be more skeptical in some areas
ADHD
CHADS score
Good content
Better DM management
Diagnostic tools and testing options
Using CHAD score
Rx IBD
Better understanding and effective treatment
ADHD scales
Evaluate patient with COPD for AAT deficiency
Early diagnosis
Better approach for Dx and treatment
Approach to patients
Screen adults for ADD
Screen for ADHD and test for AATD
Testing for ADHD
Following guidelines
More screening with patients
Prevention and education to patients and early detection
ADHD
More thorough testing of patients
Start screening for ADHD
Use of CHADS
Better understanding of diabetes
Better understanding and better management
Increase screening for osteoporosis
Better understanding of treatment modalities
Screening for AATD more often
Screening strategies for osteoporosis
Use FRAX
Will use some printed material in this symposium to improve care for my patients
Testing strategies and different approach in treatment regime
Use CHADS score
Use ADHD tool kit available online
Treatment modalities
Check AAT in all patients with COPD
Use screening tools for ADHD
Use FRAX
Improving quality of patient care management
Implement screening for ADHD
Screening for ADHD
Will use medications for treating IBD
Assessment/screening of ADHD in practice



Comment
AAT testing
Using appropriate diagnostic modalities
Use of FRAX
Management of pulmonary hypertension
Evaluation of ADHD
ADHD self assessment
Osteoporosis screening guidelines
Combination strategies
Diabetes care
ADHD medications
Use of FRAX
Earlier diagnosis
Better understanding of screening guidelines
Use of early combination in diabetes treatment
Using tools and assessments
Screening hypertension patients
Add screening and testing
Use of FRAX scoring for osteoporosis
ADHD screening
New diagnostic tools and therapies
Importance of evidence based protocols
New care and Rx therapy
Implement ADHD scales
Utilize more assessment tools for ADHD diagnosis
Increase communication with patients and relatives
Greater understanding of making the proper diagnosis and treatment of diabetes
More testing and screening
Better management of diabetes
Better management and earlier diagnosis
Start screening for AAT deficiency
Screening patients for ADHD
Do more detailed assessment of patients signs and symptoms

## What topics would you like to see offered as CME activities in the future?

Comment
More on colon/breast/ovarian cancer
HTN and recurrent UTI
Complication in high risk pregnancy
Hepatitis
Neurology for the PCP
Hypertension and CHF
Women's Health

Comment
HIV
Gout and arthritis
CHF/HTN/dementia
Dermatological conditions
Women's Health
Obesity
Acute renal failure
Sleep deprivation
CHD
Women's Health
Breast masses
Approach to patient with abnormal kidney function
Hypertension
Medical errors
HIV courses
Renal failure
Colon cancer
Infectious diseases
Medical/legal issues
Dementia
Diabetes and kidney disease
Pneumonia
COPD/asthma
Preventive medicine
Vitamin D
Men's Health
Depression
Nutrition related illnesses
Depression and gout
Rheumatology and pain
Hypertension and prostate cancer
Acute myocardial infarctions in diabetic patients
HTN
Neurology related subjects
Heart failure
CHF
Dermatology
Domestic violence
Stroke prevention
Update on hypertension
Depression
Brain injuries
Update on viral hepatitis
Men's health

Comment
More psychiatric issues
HTN and nutrition
Obesity education
Diabetes
Women's Health
Orthopedics
Sleep problems
Allergies
Radiation/oncology
CHF
HTN and dermatology
Hepatitis C
Infectious diseases
Wound care
New treatments in HIV
Bipolar disorders
Depression
Oncology topics
HIV management
Skin infections
Obesity
All of it!
Hodgkin's disease
Heart disease and women's health
Menopause treatment
Treatment of bipolar depression
Gyn malignancies
Infectious disease
Hypertension
Billing and medical economics
COPD
Pain management
Back pain
Diabetes and lipids control
Wound management
Pain management
Organ transplantation
Diabetes/HTN/Breast cancer
Dermatology

### **Additional comments:**

Comment
Excellent program

Comment
Very good conference with relevant material
Excellent program
Good course
Great conference
Excellent and I will share what I have learned
Excellent and I love the interaction with the Pre and Post questions
Very good conference
Excellent-thanks
Great staff/faculty
Offer DO credits
Very good setting and organization
Well organized conference and great information
Very good speakers-thanks
Please watch time for the speakers
Thank you
Thank you for taking time to prepare such a great event that makes us feel comfortable to learn. I liked the format of the meeting
Enjoyed the depth and the content
Excellent conference
Excellent course and location. Speakers are fantastic
Excellent program
Nice program
Great lectures
Very good
Very informative and it updated my medical knowledge
Dr. Flaherty was an excellent speaker and teacher
Very informative
Excellent course
Excellent faculty
Please send me paper copy of CME
Thank you
Excellent location
Great program
Audience response is helpful
Excellent program and staff
Thank you
Thank you
Excellent
Excellent topic and speakers
Excellent
Very good
Excellent conference
Excellent topics and speakers
This was a very informative conference

Comment
Excellent speakers
Great course
Enjoyed it
Great program overall
Excellent presentation
Great location
Please come back to South Florida. It is much better than online lectures
Great
Thank you
Dr Hershberger was excellent
Excellent overall

## Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	1.70	2.46	1.09	1.20	1.17	1.17	1.18
Variance	1.41	7.44	0.09	0.17	0.15	0.15	0.16
Standard Deviation	1.19	2.73	0.31	0.41	0.39	0.39	0.40
Standard Error	0.09	0.20	0.02	0.03	0.03	0.03	0.03
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	6.00	8.00	3.00	3.00	3.00	3.00	3.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	5.00	7.00	2.00	2.00	2.00	2.00	2.00

	Learning Objectives6	Learning Objectives7	Learning Objectives8	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care
Mean	1.12	1.07	1.09	1.27	1.38	1.29	1.40
Variance	0.11	0.07	0.12	0.26	0.26	0.21	0.28
Standard Deviation	0.33	0.26	0.34	0.51	0.51	0.46	0.53
Standard Error	0.02	0.02	0.03	0.04	0.04	0.03	0.04
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	2.00	2.00	3.00	3.00	3.00	2.00	3.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	1.00	2.00	2.00	2.00	1.00	2.00

	Make Changes	Implement New Strategies	Frank Lavernia MD {Diabetes}	Oren Mason MD {ADHD}	Franck Rahaghi MD {AAT}	Franck Rahaghi MD {PAH}	Kevin Flaherty MD {IPF}
Mean	1.46	1.59	4.66	4.73	4.81	4.81	4.84
Variance	0.54	0.83	0.37	0.27	0.17	0.16	0.15
Standard Deviation	0.73	0.91	0.61	0.52	0.42	0.40	0.38
Standard Error	0.05	0.07	0.04	0.04	0.03	0.03	0.03
Minimum	1.00	1.00	2.00	3.00	3.00	3.00	3.00
Maximum	4.00	4.00	5.00	5.00	5.00	5.00	5.00
Median	1.00	1.00	5.00	5.00	5.00	5.00	5.00
Range	3.00	3.00	3.00	2.00	2.00	2.00	2.00

	Gerald W Dryden MD {IBD}	Vernon Hershberger MD {Osteo}	Jan Basile MD {A Fib}	Frank Lavernia MD {Diabetes} Bias	Oren Mason MD {ADHD} Bias	Franck Rahaghi MD {AAT} Bias	Franck Rahaghi MD {PAH} Bias
Mean	4.79	4.82	4.87	4.92	4.86	4.91	4.89
Variance	0.24	0.21	0.17	0.10	0.21	0.11	0.12
Standard Deviation	0.49	0.46	0.41	0.31	0.46	0.33	0.35
Standard Error	0.04	0.04	0.03	0.02	0.03	0.02	0.03
Minimum	2.00	3.00	2.00	3.00	1.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	3.00	2.00	3.00	2.00	4.00	2.00	2.00

	Kevin Flaherty MD {IPF} Bias	Gerald W Dryden MD {IBD} Bias	Vernon Hershberger MD {Osteo} Bias	Jan Basile MD {A Fib} Bias	Reasons for Participating	Future CME Activities
Mean	4.91	4.89	4.88	4.91	-	1.49
Variance	0.09	0.14	0.17	0.11	-	0.44
Standard Deviation	0.30	0.37	0.41	0.33	-	0.66
Standard Error	0.02	0.03	0.03	0.03	-	0.05
Minimum	3.00	2.00	2.00	3.00	-	1.00
Maximum	5.00	5.00	5.00	5.00	-	4.00
Median	5.00	5.00	5.00	5.00	-	1.00
Range	2.00	3.00	3.00	2.00	-	3.00